North Chicago – October 19, 2026 -- AbbVie's investigational dual-targeting therapy ABBV-466 delivered endoscopic remission in 40.5% of Crohn's disease patients at Week 24, against 22.4% for risankizumab and 20.0% for trosunilimab monotherapy, according to Phase 2a TARGET-CD data (NYSE: ABBV).
ABBV-466 clears the Week 12 primary endpoint at 30.2%
At Week 12, the primary endpoint, 30.2% of ABBV-466 patients achieved endoscopic remission. Patients on anti-IL-23 p19 monotherapy (risankizumab) reached 21.3%, and those on anti-α4β7 monotherapy (trosunilimab) reached 18.0%. The gap to both monotherapy arms widened by Week 24.
ABBV-466 combines risankizumab with trosunilimab. AbbVie said its research found α4β7-driven inflammation persisting despite IL-23 p19 inhibition, which led it to add the α4β7 inhibitor to risankizumab.
Study enrolled 300 heavily pretreated patients across three arms
TARGET-CD randomized patients 1:1:1 to 24 weeks of treatment. The arms comprised 94 patients on risankizumab, 100 on trosunilimab and 106 on ABBV-466. All had moderately to severely active Crohn's disease.
Some 75% of participants had failed at least one advanced therapy, and 25% were biologic-naïve. Prior failures included IL-23 therapy in 9.3% of patients and a JAK inhibitor in 12%. A quarter had failed three or more advanced therapies.
Remo Panaccione of the University of Calgary, who is quoted in the release, said the dual-targeting approach reached remission more often than either therapy alone in a "heavily pretreated population."
Gene expression data show tissue repair by Week 12
Gene expression analyses showed colonic epithelial repair and barrier restoration in ABBV-466 patients at Week 12. Tissue remodeling and metabolic changes followed at Week 24. AbbVie said these changes were generally not observed with either monotherapy.
Serious adverse events run at 10.4%, close to monotherapy levels
Serious adverse events occurred in 10.4% of ABBV-466 patients. The rates were 9.6% for risankizumab and 9.0% for trosunilimab. The most common adverse events (≥5%) in the ABBV-466 and trosunilimab arms were Crohn's disease and nausea. In the risankizumab arm they were Crohn's disease and arthralgia.
Open-label design and investigational status frame the readout
TARGET-CD is an ongoing, open-label, treat-through Phase 2a platform study (NCT06548542), with safety assessed through Week 24. AbbVie stated that ABBV-466's safety and efficacy have not been established by regulatory authorities.
The data are being presented as a late-breaking abstract at the 2026 United European Gastroenterology Week Congress in Barcelona, running October 17–20.